We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.30 | -0.88% | 33.70 | 33.70 | 33.85 | 34.30 | 33.45 | 34.30 | 811,749 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 199.12 | 182.84M |
TIDMAPH
RNS Number : 4343G
Alliance Pharma PLC
19 July 2023
19 July 2023
ALLIANCE PHARMA PLC
("Alliance" or the " Company ")
Director Dealings
Alliance Pharma plc (AIM: APH), the international healthcare group , has been notified that Andrew Franklin, the Chief Financial Officer of the Company, purchased 50,988 ordinary shares of 1.0p each in the Company ("Ordinary Shares") at a price of 49.005 pence per share on 18(th) July 2023; and Richard Jones, a non-executive Director of the Company, purchased 53,000 Ordinary Shares at a price of 47.10 pence per share on 18(th) July 2023.
Following this transaction, (i) Mr. Franklin's total beneficial interest in the Company is 179,372 Ordinary Shares, representing 0.03% of the Company's issued share capital; and (ii) Mr. Jones' total beneficial interest in the Company is 68,000 Ordinary Shares, representing 0.013% of the Company's issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 Details of the person discharging managerial responsibilities/person closely associated a) Name Andrew Franklin -------------------------------------- --------------------------------------------------- 2 Reason for the notification ------------------------------------------------------------------------------------------- a) Position/status Chief Financial Officer -------------------------------------- --------------------------------------------------- b) Initial notification Initial Notification /Amendment -------------------------------------- --------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------------------------------------------------------------------------------------------- a) Name Alliance Pharma Plc -------------------------------------- --------------------------------------------------- b) Legal Entity 213800RYIWZA4Q5WPZ13 Identifier -------------------------------------- --------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------------------------------- a) Description Ordinary shares of 1 pence each of the financial instrument, GB0031030819 type of instrument Identification code -------------------------------------- --------------------------------------------------- b) Nature of Purchase of shares the transaction -------------------------------------- --------------------------------------------------- c) Currency GBP -------------------------------------- --------------------------------------------------- d) Price(s) Price(s) Volume(s) and volume(s) -------------------------------------- ----------------------- -------------------------- 49.005 50,988 ------------------------------------------- ----------------------- -------------------------- e) Aggregated information 50,988 Ordinary Shares, bought at a price of - Aggregated 49.005 pence per share, totalling GBP24,986.67 volume - Price - Aggregated total -------------------------------------- --------------------------------------------------- f) Date of the 18 July 2023 transaction -------------------------------------- --------------------------------------------------- g) Place of London Stock Exchange, AIM the transaction -------------------------------------- --------------------------------------------------- 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Richard Jones -------------------------------------- ------------------------------------------------- 2 Reason for the notification ----------------------------------------------------------------------------------------- a) Position/status Non Executive Director -------------------------------------- ------------------------------------------------- b) Initial notification Initial Notification /Amendment -------------------------------------- ------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ----------------------------------------------------------------------------------------- a) Name Alliance Pharma Plc -------------------------------------- ------------------------------------------------- b) Legal Entity 213800RYIWZA4Q5WPZ13 Identifier -------------------------------------- ------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------------------------- a) Description Ordinary shares of 1 pence each of the financial instrument, GB0031030819 type of instrument Identification code -------------------------------------- ------------------------------------------------- b) Nature of Purchase of shares the transaction -------------------------------------- ------------------------------------------------- c) Currency GBP -------------------------------------- ------------------------------------------------- d) Price(s) Price(s) Volume(s) and volume(s) -------------------------------------- ----------------------- ------------------------ 47.10 53,000 ------------------------------------------- ----------------------- ------------------------ e) Aggregated information 53,000 Ordinary Shares, bought at a price of - Aggregated 47.10 pence per share, totalling GBP24,963 volume - Price - Aggregated total -------------------------------------- ------------------------------------------------- f) Date of the 18 July 2023 transaction -------------------------------------- ------------------------------------------------- g) Place of London Stock Exchange, AIM the transaction -------------------------------------- -------------------------------------------------
For further information:
Alliance Pharma plc + 44 (0)1249 466966 Cora McCallum, Head of Investor Relations & Corporate Communications + 44 (0)1249 705168 ir@allianceph.com Buchanan + 44 (0)20 7466 5000 Mark Court / Hannah Ratcliff alliancepharma@buchanan.uk.com Numis Securities Limited (Nominated Adviser and Joint Broker) + 44 (0)20 7260 1000 Freddie Barnfield / Duncan Monteith / Sher Shah Investec Bank plc (Joint Broker) + 44 (0)20 7597 5970 Patrick Robb / Maria Gomez de Olea
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.
For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com
, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBIGDRCBBDGXI
(END) Dow Jones Newswires
July 19, 2023 02:00 ET (06:00 GMT)
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions